A Phase III trial of PT2977 monotherapy in patients with advanced kidney cancer
Latest Information Update: 11 Sep 2019
Price :
$35 *
At a glance
- Drugs Belzutifan (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 30 Jul 2019 According to a Merck & Co media release, Peloton Therapeutics has been acquired by Merck & Co.
- 08 Apr 2019 New trial record